Boditech Highlights Automated Benchtop and Handheld Immunoassay Readers at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022

Image: AFIAS MxA/CRP is the world’s first automated immuno-fluorescence quantitative assay (Photo courtesy of Boditech)

Boditech Med (Gang-won-do, Korea) is presenting its portfolio of latest IVD solutions, including TDM, AMS, and TB diagnostic tests, at this year's MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany.

At MEDICA 2022, Boditech is showcasing the AFIAS-1 immunoassay analyzer with an all-in-one cartridge system. The AFIAS-1 is a compact, single channel lateral flow immunoassay platform with a disposable cartridge that includes all the reagents necessary for the test. Also on display is the Boditech Quick COVID-19 Ag Nasal quick and simplified rapid test kit that determine COVID-19 antigen with a nasopharyngeal or nasal swab. Boditech Quick COVID-19 Ag Nasal can help to quickly and accurately determine the presence or absence of SARS-CoV-2 antigen at anytime and anywhere. It is very useful as a screening test for SARS-CoV-2 virus infection (COVID-19).

Among its other diagnostic tests, Boditech is highlighting the Alpha-Fetoprotein (AFP) test for diagnosing cancers (liver, testicles and ovaries) & monitoring the therapeutic effect. High levels of AFP in adults may indicate the possibility of the liver, the ovaries, or the testicles, as well as noncancerous liver diseases such as cirrhosis and hepatitis. The AFP plus measures the level of AFP to help diagnose or rule out related abnormalities. Visitors to Boditech’s booth at MEDICA 2022 can also get insights into the company’s AFIAS MxA/CRP combo test that assists in diagnosing viral & bacterial infections by measuring virus-specific markers and CRP simultaneously. The AFIAS MxA/CRP combo test is available on the company’s AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10 instruments to support the diagnosis of viral and/or bacterial infection. Boditech has also announced that it will be officially launching its new ichroma Cyfra21-1 which is a tumor marker of NSCLC (non-small cell lung cancer) in early December.

Related Links:
Boditech Med